Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury.
Acute respiratory distress syndrome (ARDS) usually requires symptomatic supportive therapy by intubation and mechanical ventilation with the supplemental use of high oxygen concentrations. Although oxygen therapy represents a life-saving measure, the recent discovery of a critical tissue-protecting mechanism predicts that administration of oxygen to ARDS patients with uncontrolled pulmonary inflammation also may have dangerous side effects. Oxygenation may weaken the local tissue hypoxia-driven and adenosine A2A receptor (A2AR)-mediated anti-inflammatory mechanism and thereby further exacerbate lung injury. Here we report experiments with wild-type and adenosine A2AR-deficient mice that confirm the predicted effects of oxygen. These results also suggest the possibility of iatrogenic exacerbation of acute lung injury upon oxygen administration due to the oxygenation-associated elimination of A2AR-mediated lung tissue-protecting pathway. We show that this potential complication of clinically widely used oxygenation procedures could be completely prevented by intratracheal injection of a selective A2AR agonist to compensate for the oxygenation-related loss of the lung tissue-protecting endogenous adenosine. The identification of a major iatrogenic complication of oxygen therapy in conditions of acute lung inflammation attracts attention to the need for clinical and epidemiological studies of ARDS patients who require oxygen therapy. It is proposed that oxygen therapy in patients with ARDS and other causes of lung inflammation should be combined with anti-inflammatory measures, e.g., with inhalative application of A2AR agonists. The reported observations may also answer the long-standing question as to why the lungs are the most susceptible to inflammatory injury and why lung failure usually precedes multiple organ failure.
Thiel
Manfred
M
Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Chouker
Alexander
A
Ohta
Akio
A
Jackson
Edward
E
Caldwell
Charles
C
Smith
Patrick
P
Lukashev
Dmitry
D
Bittmann
Iris
I
Sitkovsky
Michail V
MV
D000818:Animals; D018450:Disease Progression; D004768:Enterotoxins / Q000633:toxicity; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology*; D008070:Lipopolysaccharides / Q000633:toxicity; D051379:Mice; D010100:Oxygen / Q000633:toxicity*; D010101:Oxygen Consumption; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology*
D004768:Enterotoxins; D008070:Lipopolysaccharides; C031818:enterotoxin B, staphylococcal; D010100:Oxygen